Engineered biomimetic nanoreactor for synergistic photodynamic-chemotherapy against hypoxic tumor

• DOI: 10.1016/j.jconrel.2022.09.020
• Publication Date: 2022-09-22T04:58:05Z
• Authors: Haoyu Guo; Lutong Wang; Wei Wu; Mingke Guo; Lingkai Yang; Zhenhao Zhang; Li Cao; Feifei Pu; Xin Huang; Zengwu Shao
• Keywords: Tirapazamine; Nanoreactor; Tumor Hypoxia; Indocyanine Green; Hypoxia

Photodynamic therapy (PDT) can produce a large amount of reactive oxygen species (ROS) in the radiation field to kill tumor cells. However, sustainable anti-tumor efficacy PDT is limited due hypoxic microenvironment tumor. In this study, classic agent indocyanine green (ICG) and hypoxia-activated chemotherapeutic drug tirapazamine (TPZ) were loaded on mesoporous polydopamine (PDA) construct [email protected] nanoparticles (PIT). Then, PIT was camouflaged with cyclic arginine-glycine-aspartate (cRGD) modified cell membranes obtain engineered membrane-coated nanoreactor (cRGD-mPIT). The cRGD-mPIT could achieve dual-targeting ability via membrane mediated homologous targeting cRGD active targeting. With enhanced tumor-targeting penetrating delivery system, efficiently accumulate cells drugs quickly released response near-infrared (NIR) laser. might cytotoxic ROS under NIR further enhance hypoxia within activate TPZ, which inhibited by synergistic photodynamic-chemotherapy. Mechanically, hypoxia-inhibitory factor-1α (HIF-1α) down-regulated therapy. Accordingly, cascade effects satisfied biosafety be promising strategy